These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 27994437)

  • 1. Systemic side effects of eye drops: a pharmacokinetic perspective.
    Farkouh A; Frigo P; Czejka M
    Clin Ophthalmol; 2016; 10():2433-2441. PubMed ID: 27994437
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [A correct understanding of preservatives in eye drops].
    Liu Z; Huang C
    Zhonghua Yan Ke Za Zhi; 2015 Sep; 51(9):641-4. PubMed ID: 26693647
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Single Drop in the Eye - Effects on the Whole Body?
    Vaajanen A; Vapaatalo H
    Open Ophthalmol J; 2017; 11():305-314. PubMed ID: 29299077
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of lipid peroxidation and electron microscopic survey of maturation stages during human cataractogenesis: pharmacokinetic assay of Can-C N-acetylcarnosine prodrug lubricant eye drops for cataract prevention.
    Babizhayev MA
    Drugs R D; 2005; 6(6):345-69. PubMed ID: 16274259
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Systemic adverse effects of topical ocular instillation of atropine in two children].
    Princelle A; Hue V; Pruvost I; Potey C; Dubos F; Martinot A
    Arch Pediatr; 2013 Apr; 20(4):391-4. PubMed ID: 23433845
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanistic modeling of ophthalmic drug delivery to the anterior chamber by eye drops and contact lenses.
    Gause S; Hsu KH; Shafor C; Dixon P; Powell KC; Chauhan A
    Adv Colloid Interface Sci; 2016 Jul; 233():139-154. PubMed ID: 26318359
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systemic side effects of ophthalmic drops.
    Levy Y; Zadok D
    Clin Pediatr (Phila); 2004; 43(1):99-101. PubMed ID: 14968900
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improved ocular: systemic absorption ratio of timolol by viscous vehicle and phenylephrine.
    Kyyrönen K; Urtti A
    Invest Ophthalmol Vis Sci; 1990 Sep; 31(9):1827-33. PubMed ID: 2211028
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Infrequent systemic drug interaction: repeated syncope caused by combined treatment with timolol-containing eye drops and lercanidipine tablet].
    Kun E; Dienes L; Simonyi G; Finta E
    Orv Hetil; 2019 Feb; 160(8):309-313. PubMed ID: 30773033
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ocular drug metabolism of the bioactivating antioxidant N-acetylcarnosine for vision in ophthalmic prodrug and codrug design and delivery.
    Babizhayev MA
    Drug Dev Ind Pharm; 2008 Oct; 34(10):1071-89. PubMed ID: 18777243
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug delivery by contact lens in spontaneously glaucomatous dogs.
    Peng CC; Ben-Shlomo A; Mackay EO; Plummer CE; Chauhan A
    Curr Eye Res; 2012 Mar; 37(3):204-11. PubMed ID: 22335807
    [TBL] [Abstract][Full Text] [Related]  

  • 12. State of the art clinical efficacy and safety evaluation of N-acetylcarnosine dipeptide ophthalmic prodrug. Principles for the delivery, self-bioactivation, molecular targets and interaction with a highly evolved histidyl-hydrazide structure in the treatment and therapeutic management of a group of sight-threatening eye diseases.
    Babizhayev MA; Kasus-Jacobi A
    Curr Clin Pharmacol; 2009 Jan; 4(1):4-37. PubMed ID: 19149498
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biopharmaceutical considerations in topical ocular drug delivery.
    Davies NM
    Clin Exp Pharmacol Physiol; 2000 Jul; 27(7):558-62. PubMed ID: 10874518
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical features of glucocorticoid eye drops induced ocular hypertension in pediatric and adult uveitic eyes].
    Pei MH; Zhao C; Gao F; Zhang MF
    Zhonghua Yan Ke Za Zhi; 2018 Nov; 54(11):839-842. PubMed ID: 30440155
    [No Abstract]   [Full Text] [Related]  

  • 15. Ocular pharmacology.
    Novack GD; Robin AL
    J Clin Pharmacol; 2016 May; 56(5):517-27. PubMed ID: 26360129
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Why Chain Length of Hyaluronan in Eye Drops Matters.
    Müller-Lierheim WGK
    Diagnostics (Basel); 2020 Jul; 10(8):. PubMed ID: 32717869
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potentiation of intraocular absorption and drug metabolism of N-acetylcarnosine lubricant eye drops: drug interaction with sight threatening lipid peroxides in the treatment for age-related eye diseases.
    Babizhayev MA
    Drug Metabol Drug Interact; 2009; 24(2-4):275-323. PubMed ID: 20408504
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The unwanted ocular effects from topical ophthalmic drugs. Their occurrence, avoidance and reversal.
    Lyle WM; Hopkins GA
    J Am Optom Assoc; 1977 Dec; 48(12):1519-23. PubMed ID: 599247
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ocular bioavailability and systemic loss of topically applied ophthalmic drugs.
    Patton TF; Francoeur M
    Am J Ophthalmol; 1978 Feb; 85(2):225-9. PubMed ID: 623195
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Telomere Attrition in Human Lens Epithelial Cells Associated with Oxidative Stress Provide a New Therapeutic Target for the Treatment, Dissolving and Prevention of Cataract with N-Acetylcarnosine Lubricant Eye Drops. Kinetic, Pharmacological and Activity-Dependent Separation of Therapeutic Targeting: Transcorneal Penetration and Delivery of L-Carnosine in the Aqueous Humor and Hormone-Like Hypothalamic Antiaging Effects of the Instilled Ophthalmic Drug Through a Safe Eye Medication Technique.
    Babizhayev MA; Yegorov YE
    Recent Pat Drug Deliv Formul; 2016; 10(2):82-129. PubMed ID: 26084629
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.